医学
重症监护医学
药品
病死率
临床实习
人口
肝损伤
病理
流行病学
内科学
药理学
家庭医学
环境卫生
作者
Tom Hosack,Djamil Damry,Sujata Biswas
标识
DOI:10.1177/17562848231163410
摘要
Drug-induced liver injury (DILI) remains a challenge in clinical practice and is still a diagnosis of exclusion. Although it has a low incidence amongst the general population, DILI accounts for most cases of acute liver failure with a fatality rate of up to 50%. While multiple mechanisms of DILI have been postulated, there is no clear causal relationship between drugs, risk factors and mechanisms of DILI. Current best practice relies on a combination of high clinical suspicion, thorough clinical history of risk factors and timeline, and extensive hepatological investigations as supported by the international Roussel Uclaf Causality Assessment Method criteria, the latter considered a key diagnostic algorithm for DILI. This review focuses on DILI classification, risk factors, clinical evaluation, future biomarkers and management, with the aim of facilitating physicians to correctly identify DILI early in presentation.
科研通智能强力驱动
Strongly Powered by AbleSci AI